IRVINE, California – (BUSINESS WIRE) – GATC Health, an innovative technology company focused on Whole Genome Testing and Predictive Multiomics ™, announced today that Dr. Jonathan Lakey, co-developer of the Edmonton Protocol and world-renowned expert in diabetes and islet transplantation, has joined the company’s board of directors of consultants. The contributions and instructions from Dr. Lakey will be an integral part of the development of GATC Health’s diabetes platform, which combines multi-comic analysis with advanced machine learning to support the early detection, intervention and management of diabetes and diabetes therapies including islet and stem cell transplantation.
“Dr. Lakey is recognized nationally and internationally for his groundbreaking research in diabetes,” said John Stroh, interim CEO of GATC. “He has received numerous national awards in the field of diabetes and islet transplantation. He has also served on scientific advisory boards for several diabetes care providers. Biotechnology companies, on boards that set safety standards for cell and tissue transplantation, and on the editorial board of journals for diabetes, biomaterials and transplantation. We are honored to have him on our advisory board and look forward to his support in the development of our diabetes -Platform. ”
“GATC Health has presented me with an incredible opportunity to make significant advances in the detection and treatment of diabetes,” said Dr. Lakey. “My job is to assemble a world-class team of scientific and technical experts to further develop a diabetes-focused platform using the company’s Multiomics Advanced Technology ™ (MAT). The GATC Health Diabetes Platform has the potential to revolutionize the way we detect diabetes before it develops in an individual, and potentially halt its progression through new treatments and transplant protocols. ”
Dr. Lakey is currently Professor of Surgery and Biomedical Engineering and Director of the Clinical Islet Program at the University of California at Irvine. He received his PhD from the University of Alberta, Canada, and completed his postdoctoral training in Indianapolis and Seattle before returning to establish his research program at the University of Alberta. Dr. Lakey was also a director of the Comprehensive Tissue Bank in Edmonton. His contributions and his partnership with Dr. James Shapiro led to the improvement of islet isolation techniques and the development of the Edmonton Protocol for Patients with Type I Diabetes, a recognized major advancement in the treatment of Type I diabetes.
About GATC Health
GATC Health is a pioneering technology company using Predictive Multiomics ™ to advance drug discovery and improve human health. Multiomic Advanced Technology (MAT ™), developed by GATC Health, sequences an individual’s DNA, reads the entire genome, and analyzes the entire data set of “omics”, including genomics, proteomics and microbiomics. A complete understanding of a person’s genetics combined with assessment of other omics results in the most comprehensive individual health analysis available that can result in rapid drug development, pre-screening clinical trial participants, identifying new drugs, and reusing existing treatments. GATC Health’s innovative technology is moving healthcare from reactive to predictive – it is truly personalized medicine. For more information on GATC Health, please visit http://www.GATCHealth.com.
Disclaimer of liability
The information contained herein is for informational purposes only and should not be viewed as an offer to sell any securities. This presentation contains information that the company believes is accurate, including certain financial information and projections. However, the company does not guarantee the accuracy or completeness of this information. The company reserves the right to change or add to the information contained herein.
